Hepatocellular Carcinoma (HCC):
Osteosarcoma (OS):
Co-aggregates with Tau in Alzheimer’s disease neurofibrillary tangles, forming detergent-insoluble complexes .
Autoantibodies against SNRNP70 are hallmarks of mixed connective tissue disease (MCTD) (95% seropositivity) and 30% of systemic lupus erythematosus cases .
Recombinant Proteins:
Therapeutic Targeting:
SNRNP70 is ubiquitously expressed, with high levels in:
SNRNP70 is a key component of the U1 small nuclear ribonucleoprotein (snRNP), essential for both constitutive and alternative pre-mRNA splicing. Structurally, SNRNP70 comprises a C-terminal tail domain mediating binding with Sm proteins, an α-helix domain, an RNA recognition motif (RRM) forming contacts with U1 snRNA, and two low-complexity arginine/serine domains involved in interactions with SR proteins . While its nuclear role in splicing is well-established, recent research has uncovered significant cytoplasmic functions including local regulation of mRNA processing in neuronal axons and protection of specific transcripts from degradation .
SNRNP70 exhibits differential subcellular localization, with robust nuclear expression across various tissues but also significant cytoplasmic presence, particularly in neurons. Immunofluorescence studies in zebrafish reveal SNRNP70 immunoreactivity within motor axon terminals adjacent to acetylcholine receptor (AChR) clusters, indicating localization to neuromuscular junctions . Mosaic expression of recombinant hSNRNP70-eGFP confirms both nuclear localization in neurons and multiple eGFP puncta co-localizing with RNAs in neuronal processes, with some puncta displaying oscillatory or motile behaviors . This dual localization pattern suggests compartment-specific functions for SNRNP70.
For comprehensive analysis of SNRNP70 distribution, researchers should employ multiple complementary approaches. Immunofluorescence using specific antibodies can visualize SNRNP70 in fixed cells, while expression of fluorescently-tagged SNRNP70 (e.g., SNRNP70-eGFP) enables live-cell imaging of localization and dynamics . Western blotting of subcellular fractions provides quantitative assessment of SNRNP70 distribution between nuclear and cytoplasmic compartments, as demonstrated in hepatocellular carcinoma (HCC) studies where both nuclear and cytoplasmic expression was analyzed . For high-resolution investigation of SNRNP70 in neuronal compartments, including axons, super-resolution microscopy of RNA granules containing SNRNP70 has proven informative .
SNRNP70 plays a critical cell-autonomous role in motor neuron development and neuromuscular synaptogenesis. Studies in zebrafish models demonstrate that loss of SNRNP70 results in reduced total length and thickness of motor nerves at 28 hours post-fertilization (hpf), progressing to severely disrupted motor axonal development by 48 hpf with aberrant branches and reduced innervation of lateral myosepta . Cell transplantation experiments reveal that SNRNP70-null motor neurons transplanted into wild-type hosts show normal ventral projections but display absent or greatly reduced clustering of acetylcholine receptors (AChRs) at both axonal arbors and shafts, demonstrating SNRNP70's cell-autonomous requirement for AChR clustering at the neuromuscular junction .
The cytoplasmic pool of SNRNP70 exhibits two key mechanisms of action in neurons:
Protection of specific axonal transcripts from degradation, maintaining a pool of essential mRNAs in distal axonal compartments .
Local regulation of alternative splicing of critical transcripts such as agrin, thereby controlling formation of synapses through isoform-specific effects .
SNRNP70 localizes in RNA-associated granules in axons, forming distinct puncta that associate and move with RNAs in neuronal processes . This granular association suggests SNRNP70 participates in RNA transport and/or local RNA metabolism complexes, modulating the alternative splicing of genes associated with neuronal development and connectivity in a compartment-specific manner .
For comprehensive investigation of SNRNP70 in neural development, researchers should consider several complementary approaches:
In vivo models: Zebrafish transgenic lines such as Tg(hb9:GFP) enable visualization of motor neurons and axonal development in the context of SNRNP70 manipulation .
Genetic manipulation strategies: These include CRISPR/Cas9-mediated knockout, morpholino-based knockdown, and rescue experiments with fluorescently-tagged SNRNP70 constructs to establish specificity of observed phenotypes .
Cell-autonomous function assessment: Cell transplantation experiments involving transfer of manipulated cells into wild-type hosts help determine whether SNRNP70 functions cell-autonomously in specific developmental processes .
Live imaging approaches: Time-lapse microscopy of fluorescently-tagged SNRNP70 reveals dynamic properties of SNRNP70-containing RNA granules in neuronal processes .
SNRNP70 has been associated with various neurodegenerative diseases including Alzheimer's Disease and Amyotrophic Lateral Sclerosis (ALS) . Given SNRNP70's critical functions in both nuclear pre-mRNA splicing and cytoplasmic RNA metabolism in neurons, dysregulation of this protein may impact multiple aspects of neuronal function. The cytoplasmic functions of SNRNP70 in protecting axonal transcripts and regulating local splicing events suggest potential mechanisms by which altered SNRNP70 activity could contribute to neurodegeneration through disrupted axonal maintenance and synaptic connectivity . Further research is needed to elucidate the specific alterations in SNRNP70 function or distribution in different neurodegenerative conditions.
SNRNP70 shows promise as a biomarker for multiple clinical applications:
For optimal biomarker utility, immunohistochemical detection of SNRNP70 can be quantified using optical density (OD) values, with X-tile software analysis determining optimal cut-off points for prognostic categorization .
Several molecular approaches have proven effective for SNRNP70 manipulation in research contexts:
CRISPR/Cas9-based methods: Multiple guide RNAs targeting different regions of the SNRNP70 gene can be designed for effective knockout or knockdown. The research literature describes the use of three double-stranded guide RNA sequences targeting SNRNP70 (NM_003089.6), with the pLenti CRISPR v2 plasmid digested with BsmBI and annealed to gRNAs .
Lentiviral delivery systems: Lentiviral recombinant plasmids containing CRISPR components have been successfully used to manipulate SNRNP70 in cell lines such as SK-Hep1 .
Transgenic expression approaches: Expression of fluorescently-tagged SNRNP70 (e.g., hSNRNP70-eGFP) enables simultaneous visualization and functional rescue, as demonstrated in zebrafish models where hSNRNP70-eGFP expression rescued morphological abnormalities, motor function, and neuromuscular assembly in SNRNP70-null embryos .
Cell transplantation methods: For in vivo analysis of cell-autonomous functions, transplantation of cells with manipulated SNRNP70 expression into wild-type environments enables assessment of specific phenotypes without confounding systemic effects .
To investigate SNRNP70-RNA interactions in a compartment-specific manner, researchers should consider:
Subcellular fractionation combined with RNA immunoprecipitation: Separate isolation of nuclear and cytoplasmic compartments followed by SNRNP70 immunoprecipitation can identify compartment-specific RNA targets.
In situ RNA visualization techniques: Techniques such as FISH (fluorescence in situ hybridization) combined with SNRNP70 immunofluorescence can visualize co-localization of specific RNA targets with SNRNP70 in different cellular compartments.
Live imaging of RNA-protein dynamics: Co-expression of fluorescently-tagged SNRNP70 with RNA labeling systems (e.g., MS2-GFP) enables visualization of dynamic interactions in living cells, particularly valuable for studying RNA granules in neuronal processes .
Axon-specific analyses: For neuronal studies, compartmentalized culture systems or laser-capture microdissection of axonal segments can enable selective analysis of SNRNP70-RNA interactions in distal neuronal compartments.
Functional validation approaches: For candidate SNRNP70-regulated transcripts, targeted manipulation of binding sites or specific isoforms can confirm functional significance of interactions.
To comprehensively characterize SNRNP70-dependent splicing events, researchers should implement:
RNA-seq following SNRNP70 manipulation: Transcriptome-wide analysis after SNRNP70 knockdown, knockout, or overexpression can identify affected splice junctions and isoform switches. Compartment-specific RNA-seq (e.g., nuclear vs. cytoplasmic fractions) may reveal location-specific effects .
Targeted validation of splicing changes: RT-PCR with isoform-specific primers spanning alternative exons can validate and quantify specific splicing events, such as those affecting the agrin transcript which influences synaptogenesis .
Functional splicing reporter assays: Minigene constructs containing candidate alternatively spliced regions can test direct SNRNP70 effects on specific splicing decisions.
Integrative bioinformatic analysis: Motif analysis around differentially spliced regions combined with SNRNP70 binding data can predict direct versus indirect regulatory events.
Spatial analysis of isoform expression: In situ detection of specific splice variants in relation to SNRNP70 localization can reveal compartment-specific regulation, particularly important in polarized cells like neurons .
The mechanisms coordinating SNRNP70's distribution and function between nuclear and cytoplasmic compartments represent an important research frontier. Key questions include:
What signaling pathways or post-translational modifications regulate SNRNP70 subcellular localization?
Do specific SNRNP70 isoforms or conformational states preferentially associate with different compartments?
How is the balance between nuclear splicing functions and cytoplasmic RNA metabolism maintained, particularly during developmental transitions or in response to cellular stress?
What factors determine which subset of transcripts undergoes SNRNP70-dependent regulation in cytoplasmic compartments?
Addressing these questions will require integrated approaches combining proteomics, imaging, and functional studies across different cellular contexts and developmental stages.
The emerging roles of SNRNP70 in both cancer progression and neuronal function suggest potential therapeutic applications:
SNRNP70 likely functions within complex networks of RNA-binding proteins with context-specific interactions:
In the nucleus, SNRNP70 interacts with other spliceosomal components and SR proteins to regulate pre-mRNA splicing .
In cytoplasmic RNA granules, particularly in neurons, SNRNP70 may interact with transport factors, translational regulators, and other RNA processing proteins to coordinate local RNA metabolism .
Disease-specific alterations in SNRNP70's protein interaction network might contribute to pathological mechanisms in both cancer and neurodegenerative conditions .
Comprehensive characterization of these interaction networks across different cellular compartments, cell types, and disease states represents an important direction for future research.
The snRNP70 protein associates with U1 spliceosomal RNA, forming the U1-snRNP complex, which is a core component of the spliceosome . The U1-snRNP is the most abundant ribonucleoprotein particle in the nucleus and consists of one small uridylate-rich RNA (U1 RNA) complexed with several proteins . These proteins include the unique 68/70 kDa, A, and C polypeptides, as well as seven Sm proteins (B/B’, D1, D2, D3, E, F, G) that form a core subparticle common to all U-snRNP complexes .
Recombinant Human U1-snRNP 68kDa cDNA codes for the 70kDa isoform of the human U1-snRNP 68 protein, which lacks 66 internal amino acids outside the known epitope-containing areas . This recombinant protein is fused to a hexahistidine purification tag, facilitating its purification and use in various applications .
Autoantibodies to U1-snRNP are present in 95% of patients with Mixed Connective Tissue Disease (MCTD) and 30% of patients with Systemic Lupus Erythematosus (SLE) . Antibodies against the 68/70 kDa protein are known to have high clinical significance in MCTD patients . The use of single recombinant proteins as antigenic targets guarantees higher sensitivity and specificity in detecting these autoantibodies .
The recombinant snRNP70 protein is used in various immunological assays, including Western Blot and ELISA . It binds IgG-type human auto-antibodies and is suitable for labeling functional groups . The protein is supplied in a sterile filtered clear solution and is stable when stored at 4°C for short periods or frozen at -20°C for longer periods .